{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:48:23Z","timestamp":1780451303161,"version":"3.54.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.01395","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T11:50:41Z","timestamp":1575373841000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":67,"title":["Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study"],"prefix":"10.3389","volume":"10","author":[{"given":"Eline","family":"van Overbeeke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Whichello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Sch\u00f6lin Bywall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Nikolenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkeley S.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Guiddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Pravettoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vergani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Cleemput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhaeri","family":"Juhaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bennett","family":"Levitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther W.","family":"de Bekker-Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorien","family":"Veldwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"key":"B1","volume-title":"Change Management","author":"Barrow","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/2168479017720247","article-title":"The Rules of Engagement: CTTI Recommendations for Successful Collaborations Between Sponsors and Patient Groups Around Clinical Trials","volume":"52","author":"Bloom","year":"2018","journal-title":"Ther. Innovation Regul. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s11606-008-0520-5","article-title":"Validation of screening questions for limited health literacy in a large VA outpatient population","volume":"23","author":"Chew","year":"2008","journal-title":"J. Gen. Internal Med."},{"key":"B4","unstructured":"Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation.2010"},{"key":"B5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40271-017-0253-9","article-title":"Health preference research: an overview","volume":"10","author":"Craig","year":"2017","journal-title":"Patient"},{"key":"B6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40271-017-0222-3","article-title":"Giving patients' preferences a voice in medical treatment life cycle: the PREFER public-private project","volume":"10","author":"de Bekker-Grob","year":"2017","journal-title":"Patient"},{"key":"B7","first-page":"2","article-title":"The value of quantitative patient preferences in regulatory benefit-risk assessment","volume-title":"J. Market Access Health Policy","author":"Egbrink","year":"2014"},{"key":"B8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/CEG.S58321","article-title":"Assessment of treatment response in chronic constipation clinical trials","volume":"7","author":"Ervin","year":"2014","journal-title":"AClin. Exp. Gastroenterol."},{"key":"B9","unstructured":"Rare diseases, orphan medicines: Getting the facts straight20182018"},{"key":"B10","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health and Center for Biologics Evaluation and ResearchPatient Preference Information \u2013 Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders2016"},{"key":"B11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1080\/10810730.2011.604383","article-title":"Applicability of internationally available health literacy measures in the Netherlands","volume":"16","author":"Fransen","year":"2011","journal-title":"J. Health Commun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/jdv.13749","article-title":"A systematic review on methods used to evaluate patient preferences in psoriasis treatments","volume":"30","author":"Gutknecht","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40258-013-0028-y","article-title":"Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature","volume":"11","author":"Hauber","year":"2013","journal-title":"Appl. Health Econ. Health Policy"},{"key":"B14","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.jval.2016.02.019","article-title":"A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies","volume":"19","author":"Ho","year":"2016","journal-title":"Value In Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/mus.25411","article-title":"Patient-centered benefit-risk assessment in Duchenne Muscular Dystrophy","volume":"5","author":"Hollin","year":"2017","journal-title":"Muscle Nerve"},{"key":"B16","volume-title":"Introduction to Qualitative Research Methods in Psychology: Pearson Education Limited.","author":"Howitt","year":"2016"},{"key":"B17","article-title":"ICH Harmonised Guideline: revision of M4E guideline on enhancing the format and structure of benefit-risk information in ICH","year":"2016"},{"key":"B18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/14737167.2019.1612242","article-title":"The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management","volume":"19","author":"Jackson","year":"2019","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12911-019-0875-z","article-title":"Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review","volume":"19","author":"Janssens","year":"2019","journal-title":"BMC Med. Inf. Decision Making"},{"key":"B20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40271-019-00367-w","article-title":"Patient preferences in the medical product life cycle: what do stakeholders think? Semi-structured qualitative interviews in Europe and the USA","volume":"12","author":"Janssens","year":"2019","journal-title":"Patient"},{"key":"B21","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1017\/S0266462317000885","article-title":"Taking patient heterogeneity and preferences into account in health technology assessments","volume":"33","author":"Kievit","year":"2017","journal-title":"Int. J. Technol. Assess. In Health Care"},{"key":"B22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10198-016-0763-8","article-title":"Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment","volume":"18","author":"M\u00fchlbacher","year":"2017","journal-title":"Eur. J. Health Econ.: HEPAC: Health Econ. In Prev. Care"},{"key":"B23","article-title":"Patient centered benefit-risk project report: a framework for incorporating information on patient preferences regarding benefit and risk into regulatory assessments of new medical technology","year":"2015"},{"key":"B24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ygyno.2015.11.030","article-title":"Endpoints in clinical trials: what do patients consider important? A survey of the Ovarian Cancer National Alliance","volume":"140","author":"Minion","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-016-0444-9","article-title":"Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers","volume":"11","author":"Morel","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40271-018-0305-9","article-title":"Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind","volume":"11","author":"Mott","year":"2018","journal-title":"Patient - Patient-Centered Outcomes Res."},{"key":"B27","unstructured":"NICE provides first scientific advice on patient preference study design2019"},{"key":"B28","article-title":"Key considerations for developing & integrating patient perspectives in drug development: examination of the duchenne case study","volume-title":"Biotechnol. Innovation Organ. Parent Project Muscular Dystrophy.","author":"Selig","year":"2016"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.drudis.2019.05.001","article-title":"Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review","volume":"24","author":"Soekhai","year":"2019","journal-title":"Drug Discovery Today"},{"key":"B30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13047-017-0240-3","article-title":"Identifying the primary outcome for a randomised controlled trial in rheumatoid arthritis: the role of a discrete choice experiment","volume":"10","author":"Stamuli","year":"2017","journal-title":"J. Foot Ankle Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.drudis.2018.09.015","article-title":"Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review","volume":"24","author":"van Overbeeke","year":"2019","journal-title":"Drug Discovery Today"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40273-013-0118-6","article-title":"Why should regulators consider using patient preferences in benefit-risk assessment","volume":"32","author":"van Til","year":"2014","journal-title":"PharmacoEconomics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01009","article-title":"Factors and situations affecting the value of patient preference studies: semi-structured interviews in Europe and the US","volume":"10","author":"Whichello","year":"2019","journal-title":"Front. In Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01395\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T11:50:45Z","timestamp":1575373845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01395\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":33,"alternative-id":["10.3389\/fphar.2019.01395"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.01395","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,3]]},"article-number":"1395"}}